388 related articles for article (PubMed ID: 21237288)
1. Inhibition of the isoprenoid biosynthesis pathway; detection of intermediates by UPLC-MS/MS.
Henneman L; van Cruchten AG; Kulik W; Waterham HR
Biochim Biophys Acta; 2011 Apr; 1811(4):227-33. PubMed ID: 21237288
[TBL] [Abstract][Full Text] [Related]
2. Effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation.
Weivoda MM; Hohl RJ
Endocrinology; 2011 Aug; 152(8):3113-22. PubMed ID: 21586555
[TBL] [Abstract][Full Text] [Related]
3. A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro.
Wasko BM; Smits JP; Shull LW; Wiemer DF; Hohl RJ
J Lipid Res; 2011 Nov; 52(11):1957-64. PubMed ID: 21903868
[TBL] [Abstract][Full Text] [Related]
4. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacological control of biosynthesis pathway of mevalonate: effect on the proliferation of arterial smooth muscle cells].
Corsini A; Arnaboldi L; Quarato P; Ferri N; Granata A; Fumagalli R; Paoletti R
C R Seances Soc Biol Fil; 1997; 191(2):169-94. PubMed ID: 9255346
[TBL] [Abstract][Full Text] [Related]
6. Manipulation of isoprenoid biosynthesis as a possible therapeutic option in mevalonate kinase deficiency.
Schneiders MS; Houten SM; Turkenburg M; Wanders RJ; Waterham HR
Arthritis Rheum; 2006 Jul; 54(7):2306-13. PubMed ID: 16802371
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of squalene synthase but not squalene cyclase prevents mevalonate-mediated suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis at a posttranscriptional level.
Peffley DM; Gayen AK
Arch Biochem Biophys; 1997 Jan; 337(2):251-60. PubMed ID: 9016820
[TBL] [Abstract][Full Text] [Related]
8. Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A.
Vaidya S; Bostedor R; Kurtz MM; Bergstrom JD; Bansal VS
Arch Biochem Biophys; 1998 Jul; 355(1):84-92. PubMed ID: 9647670
[TBL] [Abstract][Full Text] [Related]
9. The intermediate enzymes of isoprenoid metabolism as anticancer targets.
Wiemer AJ; Hohl RJ; Wiemer DF
Anticancer Agents Med Chem; 2009 Jun; 9(5):526-42. PubMed ID: 19519294
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate.
Wasko BM; Dudakovic A; Hohl RJ
J Pharmacol Exp Ther; 2011 May; 337(2):540-6. PubMed ID: 21335425
[TBL] [Abstract][Full Text] [Related]
11. Statins and the squalene synthase inhibitor zaragozic acid stimulate the non-amyloidogenic pathway of amyloid-beta protein precursor processing by suppression of cholesterol synthesis.
Kojro E; Füger P; Prinzen C; Kanarek AM; Rat D; Endres K; Fahrenholz F; Postina R
J Alzheimers Dis; 2010; 20(4):1215-31. PubMed ID: 20413873
[TBL] [Abstract][Full Text] [Related]
12. Squalene synthase, a determinant of Raft-associated cholesterol and modulator of cancer cell proliferation.
Brusselmans K; Timmermans L; Van de Sande T; Van Veldhoven PP; Guan G; Shechter I; Claessens F; Verhoeven G; Swinnen JV
J Biol Chem; 2007 Jun; 282(26):18777-85. PubMed ID: 17483544
[TBL] [Abstract][Full Text] [Related]
13. HMG-CoA reductase regulation: use of structurally diverse first half-reaction squalene synthetase inhibitors to characterize the site of mevalonate-derived nonsterol regulator production in cultured IM-9 cells.
Petras SF; Lindsey S; Harwood HJ
J Lipid Res; 1999 Jan; 40(1):24-38. PubMed ID: 9869647
[TBL] [Abstract][Full Text] [Related]
14. Squalene synthase inhibition alters metabolism of nonsterols in rat liver.
Keller RK
Biochim Biophys Acta; 1996 Oct; 1303(3):169-79. PubMed ID: 8908150
[TBL] [Abstract][Full Text] [Related]
15. Targeting isoprenoid biosynthesis for drug discovery: bench to bedside.
Oldfield E
Acc Chem Res; 2010 Sep; 43(9):1216-26. PubMed ID: 20560544
[TBL] [Abstract][Full Text] [Related]
16. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.
Thompson K; Rogers MJ
J Bone Miner Res; 2004 Feb; 19(2):278-88. PubMed ID: 14969398
[TBL] [Abstract][Full Text] [Related]
17. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Yeganeh B; Wiechec E; Ande SR; Sharma P; Moghadam AR; Post M; Freed DH; Hashemi M; Shojaei S; Zeki AA; Ghavami S
Pharmacol Ther; 2014 Jul; 143(1):87-110. PubMed ID: 24582968
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory activity to protein prenylation and antifungal activity of zaragozic acid D3, a potent inhibitor of squalene synthase produced by the fungus, Mollisia sp. SANK 10294.
Tanimoto T; Ohya S; Tsujita Y
J Antibiot (Tokyo); 1998 Apr; 51(4):428-31. PubMed ID: 9630865
[TBL] [Abstract][Full Text] [Related]
19. The isoprenoid pathway and transcriptional response to its inhibitors in the yeast Saccharomyces cerevisiae.
Kuranda K; François J; Palamarczyk G
FEMS Yeast Res; 2010 Feb; 10(1):14-27. PubMed ID: 19744247
[TBL] [Abstract][Full Text] [Related]
20. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.
van Beek E; Pieterman E; Cohen L; Löwik C; Papapoulos S
Biochem Biophys Res Commun; 1999 Oct; 264(1):108-11. PubMed ID: 10527849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
